Cancer Research Technology (CRT) has announced the appointment of Dr J Barrie Ward as a non-executive director
Barrie Ward joins CRT's board of directors with significant experience that will be invaluable as the company develops and commercialises therapeutic opportunities from CRT's Development Laboratories and worldwide academic centres of excellence in drug discovery.
Ward's experiences as director of the microbiology division of Glaxo Research and Development, chief executive officer of Kudos Pharmaceuticals, and in his current positions as chairman of the board of directors of Avant Immunotherapeutics and Onyvax relate to both biotherapeutics and small molecules and is well aligned with CRT's broad development pipeline.
Furthermore Dr Ward's previous position as chairman of the board of directors and chief executive officer of Virus Research Institute will have an immediate benefit to the development and growth of CRT's new US subsidiary.
CRT also announced today that Celia Caulcott is stepping down from the board, having made significant contributions to the company during a period of unprecedented growth.
Melanie Lee, chairman of CRT, said, "We are delighted to appoint Barrie to the board.
"His depth of knowledge and specific experience will greatly contribute to CRT's goal to improve the treatment and lives of cancer patients.
"We also thank Celia for her dedication and advice over the past years."
